Table 4. Combined therapy with... | American Society of Hematology

Table 4.

Combined therapy with deferiprone and deferoxamine

						UIE, mg/24 h or mg/kg/d					Serum ferritin, μg/L
Study	No.	Duration, mo	DFP dose, mg/kg/d	DFO dose	DFO, days per week	DFP	DFO	DFP + DFO	Initial	Final	Significance, P
Wonke et al²⁵	5	6	75-110	2 g	2-6	23	36	70	6397	2439	NS
Balveer et al⁵	7^*	12	75-85	1 g	2	14	—	27	6619	3996	< .01
Mourad et al⁵⁶	11	12	75	2 g	2	—	—	49	4153	2805	< .01
Farmaki et al⁵⁷	40†	6-12	75-100	40-60 mg/kg	2-6	—	—	—	1907	385	NG
Alymara et al⁵⁸	21	6	60	50 mg/kg	6	—	0.34	0.76	3146	1799	NG
Galanello et al⁵⁹	34‡	3-10	75	20-50 mg/kg	2-5	0.37	0.48	0.77	5097	3963	NG
Kattamis et al⁶⁰	18§	12	50	2.53-3.0 g	3	0.50	0.46	0.69	4543	3297	< .007

						UIE, mg/24 h or mg/kg/d					Serum ferritin, μg/L
Study	No.	Duration, mo	DFP dose, mg/kg/d	DFO dose	DFO, days per week	DFP	DFO	DFP + DFO	Initial	Final	Significance, P
Wonke et al²⁵	5	6	75-110	2 g	2-6	23	36	70	6397	2439	NS
Balveer et al⁵	7^*	12	75-85	1 g	2	14	—	27	6619	3996	< .01
Mourad et al⁵⁶	11	12	75	2 g	2	—	—	49	4153	2805	< .01
Farmaki et al⁵⁷	40†	6-12	75-100	40-60 mg/kg	2-6	—	—	—	1907	385	NG
Alymara et al⁵⁸	21	6	60	50 mg/kg	6	—	0.34	0.76	3146	1799	NG
Galanello et al⁵⁹	34‡	3-10	75	20-50 mg/kg	2-5	0.37	0.48	0.77	5097	3963	NG
Kattamis et al⁶⁰	18§	12	50	2.53-3.0 g	3	0.50	0.46	0.69	4543	3297	< .007

DFO indicates deferoxamine; DFP, deferiprone; UIE, urine iron excretion.

One additional patient withdrew after 1 month because of gastrointestinal symptoms.

†

Significant improvement in ventricular dimensions and function and increase in myocardial T2 relaxation time.

‡

Agranulocytosis in 2 patients reversed after 4 to 5 days. One patient withdrew because of nausea. Transient moderate ALT rise in 6 HCV-negative and 12 HCV-positive patients. One patient discontinued therapy.

Agranulocytosis in 2 patients reversed.

View Large

This Feature Is Available To Subscribers Only